NRG Oncology

NRG Oncology Advancing Research. Improving Lives. NRG Oncology is a non-profit research organization formed to conduct oncologic clinical research.

Premenopausal patients w/ER-positive/HER2-negative who remain at high risk for recurrence may benefit from intensified...
06/02/2026

Premenopausal patients w/ER-positive/HER2-negative who remain at high risk for recurrence may benefit from intensified systemic therapy strategies. Yesterday at , Dr. Mamounas discussed the NRG-BR009 OFSET study that is evaluating whether adding chemotherapy to ovarian function suppression + endocrine therapy can improve outcomes compared to standard hormonal treatment alone.

1 WEEK AWAY - REGISTER for our NRG-GU015 "ARCHER" site webinar discussing the study assessments for the trial studying s...
06/02/2026

1 WEEK AWAY - REGISTER for our NRG-GU015 "ARCHER" site webinar discussing the study assessments for the trial studying shorter duration RT for patients receiving chemotherapy for bladder cancer. This webinar will be June 9th at 1:00PM ET. Register at bit.ly/NRG-ARCHER-RT

Currently enrolling patients, the NRG-BR009/OFSET study is evaluating whether adding chemotherapy to ovarian function su...
06/01/2026

Currently enrolling patients, the NRG-BR009/OFSET study is evaluating whether adding chemotherapy to ovarian function suppression + endocrine therapy can improve outcomes compared to standard hormonal treatment alone. Dr. Terry Mamounas discusses the trial during a poster session at this afternoon.

Start off your Monday morning with two NRG Oncology trials highlighted during poster sessions↪️NRG-GY036 with Dr. Yi...
06/01/2026

Start off your Monday morning with two NRG Oncology trials highlighted during poster sessions↪️NRG-GY036 with Dr. Ying Liu and NRG-GY037 with Dr. Jyoti Mayadev.

Tomorrow at , Dr. Priya Rastogi discusses the legacy NSABP B-28 study during a poster session. B-28 was a randomized tr...
05/31/2026

Tomorrow at , Dr. Priya Rastogi discusses the legacy NSABP B-28 study during a poster session. B-28 was a randomized trial comparing the worth of paclitaxel following doxorubicin/ cyclophosphamide in patients with and who had positive axillary nodes. NSABP Foundation

NRG research in continues at today with the poster session for NRG/RTOG 0521. Sebastian Medina discusses the spatial...
05/31/2026

NRG research in continues at today with the poster session for NRG/RTOG 0521. Sebastian Medina discusses the spatial transcriptomics-guided pathology biomarker as a predictor of adjuvant docetaxel in high-risk localized prostate cancer.

Our 2nd podcast episode is NOW LIVE! We are discussing the results of the just presented combination analysis in and...
05/30/2026

Our 2nd podcast episode is NOW LIVE! We are discussing the results of the just presented combination analysis in and learning more about translation research at NRG: www.NRGOncology.org/Podcast

The combined analysis of NRG studies (NRG/RTOG 9202, 9413, 9902 & 0521) will be an oral presentation this afternoon by...
05/30/2026

The combined analysis of NRG studies (NRG/RTOG 9202, 9413, 9902 & 0521) will be an oral presentation this afternoon by Dr. Krishnan Patel at . Immediately following the session at ASCO, catch our podcast episode recapping Dr. Patel's presentation.

NRG Oncology research presented at starts today with two trials highlighted during poster sessions. Check out ↪️NRG-...
05/30/2026

NRG Oncology research presented at starts today with two trials highlighted during poster sessions. Check out ↪️NRG-HN006 with Dr. Stephen Lai and NRG-HN015 with Dr. Nabil Saba.

Address

1600 John F Kennedy Boulevard
Philadelphia, PA
19103

Opening Hours

Monday 8am - 5pm
Tuesday 8am - 5pm
Wednesday 8am - 5pm
Thursday 8am - 5pm
Friday 9am - 5pm

Telephone

+12675196630

Website

Alerts

Be the first to know and let us send you an email when NRG Oncology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to NRG Oncology:

Shortcuts

Share

Category